scholarly journals The Role of Platelets in Chronic Urticaria

2016 ◽  
Vol 169 (2) ◽  
pp. 71-79 ◽  
Author(s):  
Gino Antonio Vena ◽  
Nicoletta Cassano ◽  
Angelo Valerio Marzano ◽  
Riccardo Asero
Keyword(s):  
Chronic Urticaria

THE ROLE OF MITE, HOUSE DUST AND CANDIDA ALLERGENS IN CHRONIC URTICARIA

1980 ◽  
Vol 7 (3) ◽  
pp. 197-202 ◽  
Author(s):  
Tsunemi Numata ◽  
Shoso Yamamoto ◽  
Takuso Yamura
Keyword(s):  
Chronic Urticaria ◽  
House Dust

Helicobacter pylori and chronic urticaria: The role of eradication

1998 ◽  
Vol 114 ◽  
pp. A84 ◽  
Author(s):  
P. Carnevale ◽  
L. Bierti ◽  
P. Pigatto ◽  
P. Masellis ◽  
R. de Franchis
Keyword(s):  
Helicobacter Pylori ◽  
Chronic Urticaria

scholarly journals Role of adjuvant narrow band ultraviolet B phototherapy in the treatment of chronic urticaria

2019 ◽  
Vol 64 (3) ◽  
pp. 250
Author(s):  
Iffat Hassan ◽  
Gousia Sheikh ◽  
Insha Latif ◽  
KouserSideeq Lone ◽  
Yasmeen Jabeen ◽  
...  
Keyword(s):  
Chronic Urticaria ◽  
Narrow Band ◽  
Ultraviolet B

scholarly journals Role of Latex Hypersensitivity in Patients with Chronic Urticaria

2016 ◽  
Vol 10 (4) ◽  
pp. 157-160
Author(s):  
Murat Durdu ◽  
Deniz Seçkin
Keyword(s):  
Chronic Urticaria

The Role of Neutrophils in Difficult-to-Treat Chronic Urticaria

2015 ◽  
Vol 135 (2) ◽  
pp. AB125
Author(s):  
Melanie H. Chong ◽  
Stephanie Mawhirt ◽  
Marcella R. Aquino ◽  
Mark Davis-Lorton ◽  
Luz S. Fonacier
Keyword(s):  
Chronic Urticaria

scholarly journals The Role of Anti-IgE Antibodies in Urticaria

2021 ◽  
Author(s):  
Patrizia Pepe ◽  
Victor Desmond Mandel
Keyword(s):  
Chronic Urticaria ◽  
Symptom Control ◽  
Symptomatic Treatment ◽  
Line Treatment ◽  
Ige Antibodies ◽  
H1 Antihistamines ◽  
Inducible Urticaria ◽  
Third Line ◽  
Third Line Treatment

Chronic urticaria, a common mast cell driven disease, has been considered so far an underestimated and difficult to treat disease, very often resulting in high physical, psychological and socio-economic burden. More than 60% of these patients are unresponsive to second generation H1 antihistamines, the first-line symptomatic treatment for urticaria. However, anti-IgE drugs (omalizumab and ligelizumab) showed improved activity in urticaria-treated patients with inadequate symptom control. Omalizumab has been widely proven to be very effective and well-tolerated in patients with antihistamine-refractory chronic spontaneous urticaria and inducible urticaria and is currently licensed for these indication as third-line treatment. Ligelizumab, a next-generation monoclonal anti-IgE antibody with higher affinity to IgE compared to omalizumab and a similar safety profile, has recently demonstrated to be even more effective than omalizumab. This review is focused on the role of anti-IgE antibodies in chronic urticaria.

Sign in / Sign up

Export Citation Format

Share Document